Head of Laboratory, Associate Professor
The Research Laboratory of Nanotechnology was established in May 2009.
Participation in scientific events
Researchers of the Laboratory participated in numerous symposia and conferences such as Symposium on Modern Chemical Physics, Conference on Innovation in Medicine, and much more. In addition, researchers took part in The International Nanotechnology Forum RUSNANOTECH (2009, 2010), The Russian Innovation Week
Conference and All-Russian Youth Innovation Convent,
various national and federal innovative programmes.
Participation in state assignments
Researchers of the Laboratory are involved in the following Government Projects of the Russian Ministry of Health:
- Development of inorganic carrier-based targeted drug delivery systems for the treatment of myocardial ischemia
- Experimental and clinical studies on the application of neuroprotection with pharmacological and non-pharmacological preconditioning
- Testing of cell therapy effects on various animal models of ischemia
- Experimental and clinical studies of new technique for myocardial protection from ischemia/reperfusion injury
Currently, the specialists of the Laboratory are studying a new approach to drug products and medical materials based on nanotechnology. In particular, they focus on the studies aimed at analyzing the toxicity and biological compatibility of nanomaterials and their distribution in the body. Active work is underway to create new cardioprotective drugs based on the method of active and passive targeted delivery to ischemic tissue.
Techniques have been developed for immobilizing fluorescent labels on the surface of silica and organic silica nanoparticles as well as for binding nanoparticles to a targeting ligand. Sodium fluorescein and indocyanine green are used as a fluorescent label. Annexin V is used as a targeting ligand. A technique has been developed for immobilizing silica nanoparticles with drugs – bradykinin and adenosine.
Numerous experiments have shown how carbon, silica, organic silica and magnetic nanoparticles alone and immobilized with a fluorescent label affect a living organism.
In 2012, the research team of the Laboratory received a Patent for Invention of the Russian Federation “Cardiac Protection Technique” and filed a Patent Application “Carrier for Drugs and Biologically Active Substances for the Treatment and Diagnosis, and the Method for its Preparation”.
We have developed the system for monitoring and analysis of hemodynamic parameters in the experiment. The system was implemented in the Pavlov First Saint Petersburg State Medical University, Almazov National Medical Research Centre, Institute of Experimental Medicine of the Northwest Branch of the Russian Academy of Medical Sciences, and Saint Petersburg Institute of Pharmacy. It is used in basic, applied and preclinical studies of new drugs.
Researchers of the Laboratory have been taking part in the Competition for the Best Innovative Project of St. Petersburg several years in a row.
The Laboratory closely collaborates with the Nanotechnology Department of St. Petersburg State Technological Institute (Technical University) and the Department of Solid State Chemistry of St. Petersburg State University.
Researchers of the Laboratory work in the field of innovation in collaboration with Innovation Advisory Centre “Innovation”, Innovation Support Centre of the Ioffe Physical Technical Institute of the Russian Academy of Sciences, Ingria Technopark, Rinno Center of Consulting and Innovation.
Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity / M. M. Galagudza, D. V. Korolev, D. L. Sonin [et al.] // International Journal of Nanomedicine. – 2010. – N 5. – P. 231-237.
Targeted drug delivery to ischemic heart with use of nanoparticulate carriers: Concepts, pitfalls and perspectives / M. Galagudza, D. Korolev, D. Sonin [et al.] // Journal of Manufacturing Technology Management. – 2010. – Vol. 21. – № 8. – P. 930–949.
Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles / M. Galagudza, D. Korolev, V. Postnov [et al.] // International Journal of Nanomedicine. – 2012. – N 7. – P. 1671–1678.
In Vivo Toxicity of Intravenously Administered Silica and Silicon Nanoparticles / S. Ivanov, S. Zhuravsky , G. Yukina [et al.] // Materials. – 2012. – № 5. – P. 1873—1889.
The infarct-limiting effect of cerebral ischaemic postconditioning in rats depends on the middle cerebral artery branching pattern / N. Shcherbak, M. Popovetsky, M. Galagudza [et al.] // International Journal of Experimental Pathology. – 2013. – Vol. 94. – № 1. – P. 34–38. doi: 10.1111/iep.12003.
Myocardial protection against global ischemia with Krebs-Henseleit buffer-based cardioplegic solution / S. M. Minasian, M. M. Galagudza, Y. V. Dmitriev [et al.] // J Cardiothorac Surg. – 2013. – Vol. 8: 60. doi: 10.1186/1749—8090-8-60.
The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodeling in the rat model of ischaemic heart failure / A. A. Karpov, Yu. K. Uspenskaya, S. M. Minasian [et al.] // International Journal of Experimental Pathology. – 2013. – Vol. 94. № 3. – P. 169–177. doi: 10.1111/iep.12017.